Skip to main content
Erschienen in: Tumor Biology 12/2016

17.10.2016 | Original Article

Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma

verfasst von: Lei Wang, Yu Wang, Peng-Ping Li, Rui Wang, Yue Zhu, Fang Zheng, Lin Li, Jiu-Jie Cui, Li-Wei Wang

Erschienen in: Tumor Biology | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

SAV1 is a human homolog of salvador that contains two protein-protein interaction modules known as WW domains and acts as a scaffolding protein for Hpo and Warts. SAV1 is known to be a tumor suppressor, but its clinical and prognostic implications remain elusive. This study aimed at evaluating the prognostic significance and associated expression of SAV1 in pancreatic ductal adenocarcinoma (PDAC) patients. The expression of SAV1 in tissue specimens of PDAC patients were assayed with immunohistochemistry on a tissue microarray. The correlations between SAV1 expression and clinicopathological characteristics were analyzed by Pearson’s chi-square test, Fisher’s exact test, and Spearman’s rank. The prognostic factors for overall survival were analyzed by univariate and multivariate Cox regression. The percentage of SAV1 expression in PDAC (50.6 %) was significantly lower than those in paratumor tissues (69.9 %) (P = 0.017). Expression of SAV1 was only significantly correlated with histological differentiation (P = 0.025) and N classification (P = 0.009). On multivariate analysis, elevated expression of SAV1 and N0 was a significant favorable prognostic factor of OS. Our study demonstrated for the first time that lower expression of SAV1 might be involved in the progression of PDAC, suggesting that SAV1 may be a potential prognostic marker and target for PDAC therapy.
Literatur
1.
Zurück zum Zitat Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMed
3.
4.
Zurück zum Zitat Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.CrossRefPubMedPubMedCentral Katz MH, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, Varadhachary G, Abbruzzese JL, Crane CH, Krishnan S, Vauthey JN, Abdalla EK, Lee JE, Pisters PW, Evans DB. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16:836–47.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W. The hippo pathway in biological control and cancer development. J Cell Physiol. 2011;226:928–39.CrossRefPubMed Chan SW, Lim CJ, Chen L, Chong YF, Huang C, Song H, Hong W. The hippo pathway in biological control and cancer development. J Cell Physiol. 2011;226:928–39.CrossRefPubMed
7.
Zurück zum Zitat Liu AM, Wong KF, Jiang X, Qiao Y, Luk JM. Regulators of mammalian hippo pathway in cancer. Biochim Biophys Acta. 2012;1826:357–64.PubMed Liu AM, Wong KF, Jiang X, Qiao Y, Luk JM. Regulators of mammalian hippo pathway in cancer. Biochim Biophys Acta. 2012;1826:357–64.PubMed
8.
Zurück zum Zitat Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB. Group AS, Bowtell DD, Harvey KF: the hippo pathway transcriptional co-activator, yap, is an ovarian cancer oncogene. Oncogene. 2011;30:2810–22.CrossRefPubMed Zhang X, George J, Deb S, Degoutin JL, Takano EA, Fox SB. Group AS, Bowtell DD, Harvey KF: the hippo pathway transcriptional co-activator, yap, is an ovarian cancer oncogene. Oncogene. 2011;30:2810–22.CrossRefPubMed
9.
Zurück zum Zitat Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T, Kishimoto H. The hippo pathway transcriptional co-activator, yap, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46:2364–70.PubMed Yoshikawa K, Noguchi K, Nakano Y, Yamamura M, Takaoka K, Hashimoto-Tamaoki T, Kishimoto H. The hippo pathway transcriptional co-activator, yap, confers resistance to cisplatin in human oral squamous cell carcinoma. Int J Oncol. 2015;46:2364–70.PubMed
10.
Zurück zum Zitat Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, Lim DS. The hippo-salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:8248–53.CrossRefPubMedPubMedCentral Lee KP, Lee JH, Kim TS, Kim TH, Park HD, Byun JS, Kim MC, Jeong WI, Calvisi DF, Kim JM, Lim DS. The hippo-salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:8248–53.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat ZP X, Zhu JS, Zhang Q, Wang XY. A breakdown of the hippo pathway in gastric cancer. Hepato-Gastroenterology. 2011;58:1611–7. ZP X, Zhu JS, Zhang Q, Wang XY. A breakdown of the hippo pathway in gastric cancer. Hepato-Gastroenterology. 2011;58:1611–7.
12.
Zurück zum Zitat Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M, Moriyama M. Downregulation of sav1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer. 2011;11:523.CrossRefPubMedPubMedCentral Matsuura K, Nakada C, Mashio M, Narimatsu T, Yoshimoto T, Tanigawa M, Tsukamoto Y, Hijiya N, Takeuchi I, Nomura T, Sato F, Mimata H, Seto M, Moriyama M. Downregulation of sav1 plays a role in pathogenesis of high-grade clear cell renal cell carcinoma. BMC Cancer. 2011;11:523.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Machado-Neto JA, Lazarini M, Favaro P, Franchi Jr GC, Nowill AE, Saad ST, Traina F. Ankhd1, a novel component of the hippo signaling pathway, promotes yap1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014;324:137–45.CrossRefPubMed Machado-Neto JA, Lazarini M, Favaro P, Franchi Jr GC, Nowill AE, Saad ST, Traina F. Ankhd1, a novel component of the hippo signaling pathway, promotes yap1 activation and cell cycle progression in prostate cancer cells. Exp Cell Res. 2014;324:137–45.CrossRefPubMed
14.
Zurück zum Zitat Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res. 2010;70:8517–25.CrossRefPubMedPubMedCentral Hall CA, Wang R, Miao J, Oliva E, Shen X, Wheeler T, Hilsenbeck SG, Orsulic S, Goode S. Hippo pathway effector yap is an ovarian cancer oncogene. Cancer Res. 2010;70:8517–25.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 2010;107:1437–42.CrossRefPubMedPubMedCentral Lu L, Li Y, Kim SM, Bossuyt W, Liu P, Qiu Q, Wang Y, Halder G, Finegold MJ, Lee JS, Johnson RL. Hippo signaling is a potent in vivo growth and tumor suppressor pathway in the mammalian liver. Proc Natl Acad Sci U S A. 2010;107:1437–42.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chen M, Wang M, Xu S, Guo X, Jiang J. Upregulation of mir-181c contributes to chemoresistance in pancreatic cancer by inactivating the hippo signaling pathway. Oncotarget. 2015;6:44466–79.PubMedPubMedCentral Chen M, Wang M, Xu S, Guo X, Jiang J. Upregulation of mir-181c contributes to chemoresistance in pancreatic cancer by inactivating the hippo signaling pathway. Oncotarget. 2015;6:44466–79.PubMedPubMedCentral
17.
Zurück zum Zitat Wang L, Wei D, Huang S, Peng Z, Le X, TT W, Yao J, Ajani J, Xie K. Transcription factor sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed Wang L, Wei D, Huang S, Peng Z, Le X, TT W, Yao J, Ajani J, Xie K. Transcription factor sp1 expression is a significant predictor of survival in human gastric cancer. Clin Cancer Res. 2003;9:6371–80.PubMed
18.
Zurück zum Zitat Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X, Ouyang X. Expression and prognosis value of shp2 in patients with pancreatic ductal adenocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37:7853–9.CrossRef Zheng J, Huang S, Huang Y, Song L, Yin Y, Kong W, Chen X, Ouyang X. Expression and prognosis value of shp2 in patients with pancreatic ductal adenocarcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2016;37:7853–9.CrossRef
19.
Zurück zum Zitat Gao T, Zhou D, Yang C, Singh T, Penzo-Mendez A, Maddipati R, Tzatsos A, Bardeesy N, Avruch J, Stanger BZ. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology. 2013;144:1543–53 1553 e1541.CrossRefPubMedPubMedCentral Gao T, Zhou D, Yang C, Singh T, Penzo-Mendez A, Maddipati R, Tzatsos A, Bardeesy N, Avruch J, Stanger BZ. Hippo signaling regulates differentiation and maintenance in the exocrine pancreas. Gastroenterology. 2013;144:1543–53 1553 e1541.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo signaling regulates pancreas development through inactivation of yap. Mol Cell Biol. 2012;32:5116–28.CrossRefPubMedPubMedCentral George NM, Day CE, Boerner BP, Johnson RL, Sarvetnick NE. Hippo signaling regulates pancreas development through inactivation of yap. Mol Cell Biol. 2012;32:5116–28.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. Salvador promotes both cell cycle exit and apoptosis in drosophila and is mutated in human cancer cell lines. Cell. 2002;110:467–78.CrossRefPubMed Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber D, Hariharan IK. Salvador promotes both cell cycle exit and apoptosis in drosophila and is mutated in human cancer cell lines. Cell. 2002;110:467–78.CrossRefPubMed
22.
Zurück zum Zitat Varelas X. The hippo pathway effectors taz and yap in development, homeostasis and disease. Development. 2014;141:1614–26.CrossRefPubMed Varelas X. The hippo pathway effectors taz and yap in development, homeostasis and disease. Development. 2014;141:1614–26.CrossRefPubMed
23.
Zurück zum Zitat Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. Downstream of mutant kras, the transcription regulator yap is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014;7:ra42.CrossRefPubMedPubMedCentral Zhang W, Nandakumar N, Shi Y, Manzano M, Smith A, Graham G, Gupta S, Vietsch EE, Laughlin SZ, Wadhwa M, Chetram M, Joshi M, Wang F, Kallakury B, Toretsky J, Wellstein A, Yi C. Downstream of mutant kras, the transcription regulator yap is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci Signal. 2014;7:ra42.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat MZ X, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer-. Am Cancer Soc. 2009;115:4576–85. MZ X, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT, Luk JM. Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer-. Am Cancer Soc. 2009;115:4576–85.
Metadaten
Titel
Expression profile and prognostic value of SAV1 in patients with pancreatic ductal adenocarcinoma
verfasst von
Lei Wang
Yu Wang
Peng-Ping Li
Rui Wang
Yue Zhu
Fang Zheng
Lin Li
Jiu-Jie Cui
Li-Wei Wang
Publikationsdatum
17.10.2016
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 12/2016
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5457-4

Weitere Artikel der Ausgabe 12/2016

Tumor Biology 12/2016 Zur Ausgabe

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

IT für Ärzte Nachrichten

Darauf haben viele Praxen gewartet: Das Zi hat eine Liste von Praxisverwaltungssystemen veröffentlicht, die von Nutzern positiv bewertet werden. Eine gute Grundlage für wechselwillige Ärzte und Psychotherapeuten.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.